Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 11/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809508 | 0.91 | KDM1A (0.49) | KDM1ACREBBPBRD4CHRM1WDR5 | |
| SCHEMBL17795410 | 0.88 | CREBBP (0.54) | KDM1ACREBBPBRD4WDR5NOTUM | |
| SCHEMBL17809587 | 0.84 | CREBBP (0.50) | KDM1ACREBBPBRD4WDR5NOTUM | |
| SCHEMBL17806259 | 0.83 | KDM1A (0.49) | KDM1ACREBBPBRD4CHRM1CYP11B2 | |
| SCHEMBL19368730 | 0.83 | CREBBP (0.47) | KDM1ACREBBPBRD4CHRM1 | |
| SCHEMBL23199303 | 0.80 | KDM1A (0.59) | KDM1ACREBBPBRD4CYP11B2PIK3CD | |
| SCHEMBL19663486 | 0.80 | KDM1A (0.59) | KDM1ACREBBPBRD4CYP11B2PIK3CD | |
| SCHEMBL19538911 | 0.79 | KDM1A (0.46) | KDM1ACREBBPBRD4CHRM1PIKFYVE | |
| SCHEMBL4434191 | 0.79 | CREBBP (0.77) | CREBBPBRD4 | |
| SCHEMBL17809509 | 0.79 | WDR5 (0.56) | KDM1ACREBBPBRD4WDR5NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | KDM1A 307/4885CREBBP 6/4885BRD4 11/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | KDM1A 307/4885CREBBP 6/4885BRD4 11/4885 |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | KDM1A 345/4885CREBBP 2/4885BRD4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.